Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $120.80

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $120.80.

ORKA has been the subject of a number of research reports. UBS Group increased their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wedbush set a $165.00 price target on Oruka Therapeutics in a report on Monday, April 27th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Finally, HC Wainwright increased their target price on Oruka Therapeutics from $75.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $61.93 on Monday. The company has a market capitalization of $3.73 billion, a P/E ratio of -31.92 and a beta of -0.20. Oruka Therapeutics has a one year low of $9.40 and a one year high of $91.00. The stock has a 50 day moving average price of $55.17 and a 200-day moving average price of $39.42.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts predict that Oruka Therapeutics will post -2.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $61.85, for a total value of $432,950.00. Following the sale, the insider owned 33,377 shares in the company, valued at $2,064,367.45. This trade represents a 17.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 30,765 shares of company stock worth $1,522,695. Insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics during the second quarter valued at $28,000. BNP Paribas Financial Markets increased its stake in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada increased its stake in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter valued at $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics during the third quarter valued at $39,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.